Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.
Sponsor: Centre Hospitalier de Bethune
Summary
Among patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting in multi-organ failure and early death in up to 35% of patients. Experimental data suggest that intravenous ascorbic acid (vitamin C) may attenuate inflammation and vascular injury related to sepsis or surgery. Preclinical and clinical studies also provide safety data of high dose intravenous vitamin C (\> 200mg/kg/day) with no significant adverse event reported and favorable impact on outcome. Experimental data also suggest beneficial effect of vitamin C in post-CA management with improvement of shock and multi-organ failure with potential benefit on neuroprotection and outcome. The study is a phase II multicenter prospective controlled open-label trial randomized in two parallel groups : * Expérimental group: Standard of care care for post-CA shock + Vitamin C (Vit-C) 200mg/kg/d IV (started as early as possible, no later than 1 h after randomization + thiamin (Vit B1) 200mg every 12 h during 3 days. * Control group: Standard of care care for post CA shock according international guidelines. Patient number to be enrolled : 234, Study duration :24 months and 28 days, Inclusion duration : 24 months, Patient participation : duration : 28 days
Official title: Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock: a Multicenter, Randomized Controled Trial.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
234
Start Date
2023-12-27
Completion Date
2028-01-24
Last Updated
2026-01-06
Healthy Volunteers
No
Conditions
Interventions
Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
standard treatment
no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
Locations (14)
Centre Hospitalier Universitaire d'Amiens
Amiens, France
CH d'Arras
Arras, France
Centre Hospitalier Béthune
Béthune, France
CHI Nord-Ardennes
Charleville-Mézières, France
Centre Hospitalier de Dieppe
Dieppe, France
GHEF Site Marne La Vallée
Jossigny, France
Centre Hospitalier de LENS
Lens, France
Centre Hospitalier Universitaire de LILLE
Lille, France
CH de Melun (GHSIF)
Melun, France
Hôpital Lariboisière
Paris, France
Centre Hospitalier de Rouen
Rouen, France
Centre Hospitalier Toulon La Seyne sur Mer
Toulon, France
Centre Hospitalier de Valenciennes
Valenciennes, France
CH de Versailles
Versailles, France